Progression-Free Survival Extended.

PositionBREAST CANCER INHIBITORS - Talazoparib - Brief article

The PARP inhibitor talazoparib extended progression-free survival and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes in a randomized Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, Houston.

"The trial found that talazoparib provides a significant clinical benefit to all patient subgroups, including those with hormone receptor-positive and triple-negative disease," says Jennifer Litton, associate professor of breast medical oncology. "The results of this trial are quite exciting and indicate talazoparib is a novel treatment option for patients with metastatic breast cancer and BRCA mutations."

Current therapies for metastatic cancer include sequential hormonal therapies and chemotherapies, but there are no approved therapies specifically for patients with metastatic breast cancer and a known BRCA mutation.

Mutations in the BRCA1/2 genes, which account for five percent to 10% of all breast cancers, cause defects in normal DNA damage repair...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT